masthead-news

News & Events

Categories

Reset Categories

Filter by Topics

AACR AMP ASCO Biomarker Discovery Bristol-Myers Squibb CDx Centre Leon Berard Clinical Biomarker CMDCAS Conference Conference Call Daiichi Sankyo Durviz ESHG FFPE Financial Results Forums Gamidor Genomeweb HTG HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBLCL Cell of Origin Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq System HTGEdgeSeq IAP IHC Illumina Immuno-Oncology ISO 13485 IVD Merck KGaA Molecular Profiling Nasdaq Nature Research Custom Media Webcast Nature.com NGS NSCLC Patents Platform comparison PMWC Presentation QIAGEN Reports RNA-Seq Sequencing Symposium Thermo Fisher Transcriptome VERI/O Laboratory Services Webinar WIN Consortium WIN Symposium
Reset Filter Reset All

HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb

TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational research activities.

Read More

Posted on:
 

HTG Molecular Diagnostics to Hold 2016 First Quarter Financial Results Conference Call on May 12, 2016

TUCSON, Ariz., May 02, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 first quarter financial results after market close on Thursday, May 12, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, May 12 to discuss these results and answer questions.

Read More

Posted on:
 

HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

TUCSON, Ariz., April 11, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.

Read More

Posted on:
 

HTG Molecular Diagnostics Announces IVD Development and Supply Agreement with Thermo Fisher Scientific

TUCSON, Ariz., March 21, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has entered into a long-term agreement with Thermo Fisher Scientific under which HTG will have the right to develop a number of in-vitro diagnostic (IVD) tests for use with Thermo Fisher’s next-generation sequencing Ion PGM Dx System.

Read More

Posted on:
 

HTG Molecular Diagnostics to Hold 2015 Fourth Quarter and Full Year Financial Results Conference Call on March 24, 2016

TUCSON, Ariz., March 15, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2015 fourth quarter and full year financial results after market close on Thursday, March 24, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, March 24 to discuss these results and answer questions.

Read More

Posted on:
 

HTG Molecular Diagnostics Establishes Immuno-Oncology Scientific Advisory Board

TUCSON, Ariz., Feb. 16, 2016 (GLOBE NEWSWIRE) – In a release issued under the same headline earlier today by HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), please note that in the header for the fourth paragraph of the release, the HTG SAB member should be Ignacio I. Wistuba, M.D. and not Ignatio I. Wistuba, M.D. as previously stated. The corrected release follows:

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced the establishment of a Scientific Advisory Board (“SAB”) of distinguished leaders in the field of immuno-oncology. The newly formed SAB will serve as a resource to HTG in the development of immuno-oncology applications and biomarker panels for the assessment of the host immune response to tumors.

Read More

Posted on:
 

HTG Molecular Diagnostics to Present at the Leerink Partners 5th Annual Global Healthcare Conference

TUCSON, Ariz., Jan. 27, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 in New York.

Read More

Posted on:
 

Personalized Medicine World Conference (PMWC) ‘16

Genetics-Informed Personalized Immunotherapy hosted by session chair Pat Roche, Ph.D, SVP for Research and Development, HTG Molecular Diagnostics with guest speakers​ Patrice Hugo, Ph.D., CSO, Q2 Solutions and Cariad Chester, Systems Immunology and Cancer Immunotherapy Research, Stanford University School of Medicine

Read More

Posted on:

Page last updated March 20, 2023